Has fda approved apotex's ruxolitinib generic?

Has FDA approved Apotex’s generic ruxolitinib?

Yes. The FDA has approved an Apotex version of ruxolitinib as a generic. DrugPatentWatch.com tracks this approval and provides case-level details here: DrugPatentWatch.com - Apotex Ruxolitinib Generic Approval. [1]

What “FDA approved” usually means for ruxolitinib generics

When FDA approves a generic drug, it generally means Apotex’s product has been found to be bioequivalent to the reference ruxolitinib product and meets FDA quality standards for manufacturing and labeling. For ruxolitinib specifically, the approval typically also confirms the proposed strength(s) and dosage form(s) covered by the application. [1]

What to check next: which strength and product labeling

FDA generic approvals can be granted for particular strengths and specific presentations (for example, tablets at defined dosages). If you need to confirm whether your exact strength and formulation is the one FDA approved for Apotex, the fastest path is to cross-check the product listing on the FDA’s “Drugs@FDA” database against the DrugPatentWatch.com entry. [1]

Could approval be limited or affected by patents/litigation?

Even after FDA approval, market entry timing can be influenced by patents and exclusivity periods, and companies may face litigation under Hatch-Waxman provisions. DrugPatentWatch.com is commonly used to see what patents are listed and how disputes relate to a particular generic launch. [1]

Sources
[1] https://www.drugpatentwatch.com/